Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks
In a report published Tuesday, JMP Securities named three biotech stocks it is watching: Acceleron Pharma Inc (NASDAQ: XLRN), Cardiovascular Systems Inc (NASDAQ: CSII) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).
Acceleron’s (Market Outperform, $52 price target) early stage clinical results at ASCO Genitourinary(GU) 2015 “support a positive outlook for maturing PFS results while providing encouragement for ongoing later stage development.”
According to analyst Michael G. King, the data is “not only encouraging because of the continued exceptional overall response rate (ORR) of 25% described in the abstract, but also because of the insight into the expected progression free survival of the fully mature Part I dataset.”
Cardiovascular Systems (Market Outperform, $44 price target) on Monday released its two-year data from its ORBIT II study of the Diamondback 360 Coronary Orbital Atherectomy System (OAS) in treating severely calcified lesions.
“The new data reaffirms that CSI’s orbital atherectomy technology is a safe and effective treatment option for severely calcified arteries. The MACE rate at two years was 19.8%, up only slightly from 16.4% at one year. MI rates remained unchanged at 9.7%. We are encouraged by these positive clinical results and believe that they will continue to drive adoption of orbital atherectomy in the coronary setting.”
Karyopharm (Market Outperform, $57 price target) recently published data “demonstrating the reduction of disease progression in two separate mouse models of multiple sclerosis with two Selective Inhibitors of Nuclear Export (SINE) compounds of exportin 1 (XPO-1). This decrease was attributed to two main mechanisms by the SINE compounds: a) via reduction of neuronal inflammation; and b) by prevention of toxic factors in the brain from causing damage to the neuronal myelin coating.”
According to King, “these data highlight a meaningful and potential clinical opportunity for the oral drug KPT-350 that is currently in development for inflammatory and autoimmune diseases; and specifically, for multiple sclerosis (MS) patients who are averse to infusions or injections with leading treatments on the market, such as Avonex (BIIB, NC) or Copaxone (TEVA, NC) or are unable to tolerate the GI issues that may be associated with an oral drug like Tefcidera (BIIB, NC).”
Latest Ratings for XLRN
Date
Firm
Action
From
To
Aug 2014
Leerink Swann
Initiates Coverage on
Outperform
Aug 2014
FBR Capital
Initiates Coverage on
Outperform
Dec 2013
JMP Securities
Maintains
Market Outperform
View More Analyst Ratings for XLRN
View the Latest Analyst Ratings
See more from Benzinga
DA Davidson On Salesforce.com: ‘The Most Important Earnings Report in the History of SaaS?’
This Options Trader Provides A Technical View On 3D Systems
ECB Announces New €20 Bill, Uses Tetris To Promote Its Security Features
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Investment & Company Information
Finance
Cardiovascular Systems
View article –
Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks
